Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sally Ball

Internal Medicine Shreveport, LA Medical Doctor

NPI 1568441251 CMS profile 834782

8001 Youree Dr, Suite 400, Shreveport, LA 71115

Open in the dashboard

General payments

$6,653

439 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sally Ball of Shreveport, LA is reported in the CMS Open Payments database as having received $6,653 across 439 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $615 36
2024 General $831 52
2023 General $1,465 94
2022 General $1,637 117
2021 General $1,122 89
2020 General $644 38
2019 General $338 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sally Ball
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Sally Ball were reported at $615. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Sally Ball Internal Medicine median Middle half National median
2019 $338 $159 $48–$570 $163
2020 $644 $119 $33–$402 $114
2021 $1,122 $135 $37–$521 $132
2022 $1,637 $141 $42–$496 $149
2023 $1,465 $149 $45–$519 $160
2024 $831 $154 $47–$537 $164
2025 $615 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Daiichi Sankyo Inc. $2,027 138 payments
  2. Pfizer Inc. $427 28 payments
  3. Lilly USA, LLC $423 29 payments
  4. Novo Nordisk Inc $392 23 payments
  5. AbbVie, Inc. $375 55 payments
  6. ACADIA Pharmaceuticals Inc $324 17 payments
  7. GlaxoSmithKline, LLC. $241 13 payments
  8. AstraZeneca Pharmaceuticals LP $200 13 payments
  9. Merck Sharp & Dohme Corporation $195 13 payments
  10. Amgen Inc. $165 10 payments
  11. Other $1,884 100 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,633 438 payments
  2. Education $20 1 payment
Products named General payments · program years 2019–2025
  1. INJECTAFER Iron Deficiency Anemia $1,695 121 payments
  2. INJECTAFER Anemia $332 17 payments
  3. MOUNJARO $293 19 payments
  4. ELIQUIS $283 19 payments
  5. Ozempic $271 16 payments
  6. RYBELSUS $238 14 payments
  7. NUPLAZID $231 12 payments
  8. SHINGRIX $199 10 payments
  9. STEGLATRO $154 10 payments
  10. QULIPTA $153 19 payments
  11. Other $4,363 288 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 126 drugs

Part D claims

8,118

Median for Internal Medicine: 777

Drug cost

$550,905

Median for Internal Medicine: $73,373

Branded share of claims

14.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 125 $154,524
Trulicity Dulaglutide Brand 72 $92,890
Eliquis Apixaban Brand 46 $49,983
Mounjaro Tirzepatide Brand 43 $46,669
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 53 $39,993
Xarelto Rivaroxaban Brand 19 $23,627
Januvia Sitagliptin Phosphate Brand 16 $14,225
Linzess Linaclotide Brand 19 $9,829
Premarin Estrogens, Conjugated Brand 13 $7,064
Atorvastatin Calcium Generic 750 $6,709

The 10 drugs with the highest cost, of 126 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$149,355

Of which drugs: $9,837

Medicare patients

432

Average age 76

Services billed

2,672

337 women, 95 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Diabetes 31%
Ischemic heart disease 27%
Depression 27%
Osteoporosis 27%
Chronic kidney disease 24%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 25 26 $7,456
Vaccine for influenza for injection into muscle 90662 Office 24 24 $1,944
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 20 67 $331
Injection, ketorolac tromethamine, per 15 mg J1885 Office 14 84 $45
Injection, ceftriaxone sodium, per 250 mg J0696 Office 16 76 $24
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 11 106 $9

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INJECTAFER
  • Daiichi Sankyo Inc. $239
$239 — —
REXULTI
  • Lundbeck LLC $64
  • Otsuka America Pharmaceutical, Inc. $23
$87 — —
MOUNJARO
  • Lilly USA, LLC $51
$51 43 —
SHINGRIX
  • GlaxoSmithKline, LLC. $32
$32 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $28
$28 125 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

439 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record